Acute and subacute toxicity in vivo of thermal-sprayed silver containing hydroxyapatite coating in rat tibia.
To reduce the incidence of implant-associated infection, we previously developed a novel coating technology using hydroxyapatite (HA) containing silver (Ag). This study examined in vivo acute and subacute toxicity associated with the Ag-HA coating in rat tibiae. Ten-week-old rats received implantation of HA-, 2% Ag-HA-, or 50% Ag-HA-coated titanium rods. Concentrations of silver in serum, brain, liver, kidneys, and spleen were measured in the acute phase (2-4 days after treatment) and subacute phase (4-12 weeks after treatment). Biochemical and histological examinations of those organs were also performed. Mean serum silver concentration peaked in the acute phase and then gradually decreased. Mean silver concentrations in all examined organs from the 2% Ag-HA coating groups showed no significant differences compared with the HA coating group. No significant differences in mean levels of glutamic-oxaloacetic transaminase, glutamic-pyruvic transaminase, lactate dehydrogenase, creatinine, or blood urea nitrogen were seen between the three groups and controls. Histological examinations of all organs revealed no abnormal pathologic findings. No acute or subacute toxicity was seen in vivo for 2% Ag-HA coating or HA coating. Ag-HA coatings on implants may represent biologically safe antibacterial biomaterials and may be of value for reducing surgical-site infections related to implantation.
Department of Orthopedic Surgery, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan.
Masatsugu
M
Tsukamoto
Departments of Pathology and Microbiology, Faculty of Medicine, Saga University, Saga 849-8501, Japan.
Hiroshi
H
Miyamoto
Research Department, KYOCERA Medical Corporation, Osaka 532-0003, Japan.
Yoshiki
Y
Ando
Departments of Pathology and Microbiology, Faculty of Medicine, Saga University, Saga 849-8501, Japan ; Research Department, KYOCERA Medical Corporation, Osaka 532-0003, Japan.
Iwao
0000-0001-9511-5473
I
Noda
Department of Orthopedic Surgery, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan.
Shuichi
S
Eto
Department of Orthopedic Surgery, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan.
Takayuki
T
Akiyama
Department of Orthopedic Surgery, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan.
Yutaka
Y
Yonekura
Department of Orthopedic Surgery, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan.
Motoki
0000-0001-7786-8957
M
Sonohata
Department of Orthopedic Surgery, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan.
Masaaki
M
Mawatari
D000818:Animals; D000900:Anti-Bacterial Agents; D020099:Coated Materials, Biocompatible; D017886:Durapatite / Q000009:adverse effects* / Q000627:therapeutic use; D019736:Prostheses and Implants / Q000009:adverse effects*; D051381:Rats; D012834:Silver / Q000009:adverse effects / Q000627:therapeutic use*; D013977:Tibia / Q000254:growth & development / Q000473:pathology / Q000601:surgery; D014025:Titanium / Q000009:adverse effects* / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D020099:Coated Materials, Biocompatible; D012834:Silver; D017886:Durapatite; D014025:Titanium